How can we optimize the process development of a viral vector: Example for an Adeno Associated Virus?

Adeno-associated virus (AAV) vectors elicit robust and long-term transgene expression in vivo together with minimal immunogenicity and little to no toxicity that make AAV vectors ideally suited for many gene therapy.

Manufacturing technologies for the production of these clinical grade viral vectors have been significantly improved in recent years. Challenges regarding production and purification are step by step overpassed leading to higher yield within less operating time.

In this presentation we will show significant improvement for AAV vectors in term of production automation and small scale purification for the optimization of their process development.